In this issue:
Ponesimod vs teriflunomide for relapsing MS
Long-term evolution of MS iron rim lesions in 7 T MRI
DMT use for relapsing-remitting MS in Australia (1996-2019)
Decision making and framing effects in MS
The efficiency of mirror therapy on drop foot in MS
Menstrual cycle resumption and fertility after AHSCT for MS
DMTs for MS and the risk for reporting cancer
CNS inflammation after natalizumab for MS
SARS-CoV-2 antibodies in patients with MS
Epileptic seizures in MS
Please login below to download this issue (PDF)